Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

DAIICHI SANKYO, INC.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Subsidiary

Established: 2010-01-01

Employees: 10K

Market Cap: $79B

Website: http://daiichisankyo.us

Clinical Trials

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

Phase 1

Terminated

Conditions: Gastrointestinal Stromal Tumor (GIST)
Ovarian Cancer
Squamous Cell Carcinoma of the Head and Neck
Melanoma
Non-small Cell Lung Cancer

Interventions: Drug: PLX3397
Biological: Pembrolizumab

First Posted Date: 2015-05-22

Last Posted Date: 2020-03-05

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 78

Registration Number: NCT02452424

Locations: 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
Marin Cancer Care, Greenbrae, California, United States
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

and more 9 locations

A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: CS-3150

First Posted Date: 2015-05-19

Last Posted Date: 2019-10-08

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 33

Registration Number: NCT02448628

Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)

Phase 3

Completed

Conditions: Pigmented Villonodular Synovitis
Giant Cell Tumors of the Tendon Sheath
Tenosynovial Giant Cell Tumor

Interventions: Drug: Pexidartinib
Drug: Placebo

First Posted Date: 2015-02-25

Last Posted Date: 2022-05-11

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 120

Registration Number: NCT02371369

Locations: 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Stanford Cancer Center, Palo Alto, California, United States

and more 35 locations

Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Phase 1

Completed

Conditions: Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Patritumab
Drug: Cetuximab
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2015-01-30

Last Posted Date: 2018-09-11

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 15

Registration Number: NCT02350712

Locations: 🇬🇧
The Royal Marsden Hospital, London, United Kingdom
🇬🇧
University College London Hospital, London, United Kingdom

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria

Phase 2

Completed

Conditions: Diabetic Nephropathy

Interventions: Drug: CS-3150
Drug: placebo

First Posted Date: 2015-01-26

Last Posted Date: 2018-12-21

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 365

Registration Number: NCT02345057

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects

Phase 2

Completed

Conditions: Essential Hypertension

Interventions: Drug: CS-3150
Drug: placebo
Drug: eplerenone

First Posted Date: 2015-01-26

Last Posted Date: 2019-10-08

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 426

Registration Number: NCT02345044

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Phase 1

Terminated

Conditions: Acute Myelogenous Leukemia
Myelodysplastic Syndrome

Interventions: Drug: Milademetan
Drug: AZA

First Posted Date: 2014-12-18

Last Posted Date: 2021-10-11

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 74

Registration Number: NCT02319369

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
University of California San Francisco Medical Center, San Francisco, California, United States
🇺🇸
University of Kansas Cancer Center, Fairway, Kansas, United States

and more 2 locations

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study

Phase 1

Completed

Conditions: Venous Thromboembolism
Deep Vein Thrombosis

Interventions: Drug: Edoxaban high dose
Drug: Edoxaban low dose

First Posted Date: 2014-12-01

Last Posted Date: 2023-10-11

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 66

Registration Number: NCT02303431

Locations: 🇺🇸
University of California, Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
🇺🇸
University of Colorado Denver, Denver, Colorado, United States

and more 32 locations

Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease

Phase 1

Completed

Conditions: Chronic Renal Disease
Renal Anemia

Interventions: Drug: DS-1093a

First Posted Date: 2014-11-24

Last Posted Date: 2018-12-24

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 31

Registration Number: NCT02299661

Locations: 🇨🇿
: Hemodialysis Center, Teaching Hospital Hradec Králove, Hradec Kralove, Czechia
🇭🇺
PRA Clinical Pharmacology Unit, Budapest, Hungary

Relative Bioavailability DS-1971a Suspension and Tablets and Food Effect on DS-1971a Tablets

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: DS-1971a tablet
Drug: DS-1971a suspension

First Posted Date: 2014-10-17

Last Posted Date: 2018-12-24

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 18

Registration Number: NCT02266940

Locations: 🇬🇧
Hammersmith Medicines Research Ltd, London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy